Duc Nguyen
Primary Podiatric Medicine · Garden Grove, CANPI 1245495498
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Integra Lifesciences Corporation accounts for 61.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $794 and has fallen 86.4% since, to $108 in 2025.
Across 42 payments — averaging $35.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Integra Lifesciences Corporation$912
- Smith+Nephew$191
- Bioventus LLC$106
- Medtronic$100
- Nevro Corp.$66
- Stryker$36
- plus $68 from 3 others
What the payments were for
- Food & beverage$1,478100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Integra Lifesciences Corporation | 31 | $912 |
| Smith+Nephew | 4 | $191 |
| Bioventus LLC | 1 | $106 |
| Medtronic | 1 | $100 |
| Nevro Corp. | 1 | $66 |
| Stryker | 1 | $36 |
| Averitas Pharma Inc. | 1 | $24 |
| Merck | 1 | $23 |
| Inari Medical, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,478 in reported general payments places this provider in the 60th percentile of 59 primary podiatric medicine providers in California.
See all primary podiatric medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 37 | $1,486 |
| Ketoconazole | 24 | $744 |
| Alendronate Sodium | 21 | $202 |
| Cephalexin | 23 | $77 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $46 |
Paid to pharmacies, not to this prescriber.
Other primary podiatric medicine in Garden Grove
- Marie ShinGarden Grove$732
- James WangLos Angeles$250K
- Adam ShapiroUpland$21K
- Ali GhorbanifarajzadehBakersfield$17K
- Abid ChaudhryArleta$11K
- Matthew GarrisonSacramento$7K
- Linh HuynhTurlock$7K
- Yvette CanabaSantee$5K
- David KhakshoorLos Angeles$4K
- Katrina SergeevaVista$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.